Cyfuse Biomedical K.K. [4892.T]
TOKYO, Mar 27 (Pulse News Wire) – Cyfuse Biomedical K.K. (4892.T) resolved to issue restricted shares as part of its executive compensation plan during a board meeting held.
The issuance includes ordinary shares worth up to ¥60.5 million to directors and up to ¥12.1 million to senior executives. Share deliveries will occur on April 24, 2026, subject to vesting conditions tied to continued employment until April 23, 2036. Under the new equity incentive program, directors and senior executives will receive shares with restrictions on transfers for a set period. These shares will be granted based on performance and tenure requirements aimed at aligning management interests with shareholder value.
The company's board approved the issuance following a resolution at the 13th Annual General Meeting held on March 28, 2023. Shareholders' approval allowed for separate tranches of cash awards and stock grants within defined limits. The board also decided to extend the scheme to senior executives who are not concurrently serving as directors. All recipients must agree to vesting agreements stipulating share retention until their respective service periods end.
🟢 Confidence: High AI-translated content.